Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5  Years

ConclusionLong-term tafamidis treatment may confer survival benefit in patients with ATTR-PN.Trial registrationClinicalTrials.gov identifier: NCT00409175, NCT00791492, NCT00630864, and NCT00925002.
Source: Neurology and Therapy - Category: Neurology Source Type: research